NextCell Pharma: Follow-up comment - Redeye

Redeye returns with an updated take on NextCell following the inconclusive interim analysis, which has led to a sharp decline in the share price. We make adjustments to our valuation model leading to a revised base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1093364/nextcell-pharma-follow-up-comment?utm_source=finwire&utm_medium=RSS